Page 1 of 1

EU says MS drug Gilenya needs heart monitoring

Posted: Mon Jan 23, 2012 12:26 am
by MSUK
Image

The European Medicines Agency advised doctors to continuously monitor patients for six hours after giving them a first dose of Novartis AG's multiple sclerosis drug Gilenya, casting a shadow over the potential blockbuster product.

The move came as the organisation started a review into the safety of the medicine, following reports of heart problems in patients and the death of one person in the United States within 24 hours of starting treatment.

The Swiss drugmaker said last month it was investigating whether Gilenya, seen by analysts as a potential multibillion-dollar seller, caused the death of the 59-year-old U.S. patient....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... geid/1309/

Re: EU says MS drug Gilenya needs heart monitoring

Posted: Sat Feb 25, 2012 10:59 am
by arabia
thanks for sharing